Efficacy and cytokines of lenalidomide therapy in Japanese patients with relapsed or refractory multiple myeloma
Not Applicable
Recruiting
- Conditions
- Multiple Myeloma
- Registration Number
- JPRN-UMIN000007206
- Lead Sponsor
- Kansai Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
•Cardiac infarction within 6 months •Deep vein thrombosis or pulmonary embolism within 3 years •Tuberculosis, herpes simplex keratitis, mycosis, or other active infections at baseline •Uncontrollable diabetes mellitus, hypertension, peptic ulcer, or glaucoma •Posterior capsule opacification •Patients with mental illness •Those who are considered as inappropriate to register by attending physicians •Pregnant or breast feeding females •Known hypersensitivity to dexamethasone
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Association of plasma cytokine changes with response rate, PFS, OS and safety of lenalidomide therapy Association between factors for thromboembolism and adverse events of lenalidomide therapy